AKT1 and neoplasm: MAP3K9, as an MAPK, activates the AKT-related pathway, which promotes degradative phosphorylation of GSK3β, induces degradation of the β-catenin degradation complex (actin/GSK3β/APC), stabilizing β-catenin in the cytoplasm, with abnormal cellular deposition of β-catenin resulting in tumor related events (42–45).